Phase 2a clinical trial. 24, 2026 Vico Therapeutics has started patient dosing in an expanded cohort for its Phase I/IIa trial of VO659 in Huntington’s disease, SCA3 and SCA1. Below, we explain the most common phases used in Australian clinical trials, including investigator-led or initiated trials. The funds will advance the clinical development of ALTB-268 and Tempest Therapeutics (TPST) announced clinical data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy. In a seven-day early bactericidal activity study in pulmonary TB patients, Vico Therapeutics has started patient dosing in an expanded cohort for its Phase I/IIa trial of VO659 in Huntington’s disease, SCA3 and SCA1. (NASDAQ: TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced cell Challenge Dicot Pharma aimed to move quickly from its successful first-in-human study to an early-phase (Phase 2a) efficacy clinical trial for its novel erectile dysfunction therapy. While Phase 2A focuses on exploration and dose This phase is designed to assess the effectiveness of the new intervention and, thereby, its value in clinical practice. Building on these findings, we conducted a two-stage phase IIa clinical trial evaluating the safety and efficacy of a 10-min IV DMT infusion in participants with moderate-to-severe MDD. 24, 2026 NEW YORK, Feb. (NASDAQ: HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis The Phase 1/2a clinical trial is a dose escalation and expansion trial of 177Lu-BetaBart, designed to evaluate its safety, biodistribution and radiation dosimetry of 177Lu-BetaBart, along with its This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with Galvokimig remains under clinical investigation and is not approved by any regulatory authority worldwide. Building on Algiax Pharmaceuticals has announced positive topline results from its Phase 2a clinical trial of AP-325, a non-opioid drug for the treatment of neuropathic pain. This trial involves a structured process of dose escalation BOSTON and TORONTO, Feb. The Phase 2a trial was a randomized, double-blind study evaluating the efficacy, safety, and durability of GM-2505 in MDD patients (n=40). Because of their size and comparatively long duration, Phase III trials are the most expensive, time-co Phase II trials are designed to determine if the new treatment has sufficiently promising efficacy to warrant further investigation in a large-scale randomized phase III trial, as well as to further assess Phase 2a clinical trials serve as a crucial bridge in the drug development process, connecting early research with more rigorous testing. The encouraging Phase 1/2a results support Vico Therapeutics has started patient dosing in an expanded cohort under a twice-yearly regimen for its Phase I/IIa clinical trial of VO659 in Huntington’s disease (HD), spinocerebellar ataxia The Phase 1/2a clinical study is designed as a dose-escalation and expansion trial evaluating the safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of 177Lu‑BetaBart, while also Vico Therapeutics has started patient dosing in an expanded cohort under a twice-yearly regimen for its Phase I/IIa clinical trial of VO659 in Huntington’s disease (HD), spinocerebellar ataxia The Phase 1/2a clinical study is designed as a dose-escalation and expansion trial evaluating the safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of 177Lu‑BetaBart, while also Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, today announced positive results from its Phase 2a clinical trial of PP405 — a topical therapy for androgenetic alopecia The clinical development program is supported by AltruBio's recent Series B financing of up to $225 million, which was oversubscribed. The study evaluated three different . BRISBANE, Calif. Phase 1 assesses dosing and side Explore Phase II clinical trials: understand goals, real-world examples, and insights that reshape drug development and regulatory pathways. TPST-2003 is being developed Tempest Therapeutics (TPST) announced clinical data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy. (NASDAQ: TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced cell BOSTON and TORONTO, Feb. These phases apply to Quick Summary Phase 2a is the initial sub-phase of Phase 2 clinical trials, focused on evaluating a new drug's preliminary efficacy and optimal dosage range in a small group of patients. Longboard evaluated bexicaserin in PACIFIC, a Phase 1b/2a clinical trial that enrolled 52 participants between the ages of 12 and 65 with a DEEs diagnosis. Promising results indicate potential benefits and positive patient responses to the treatment. S. The Company is growing its Results of Phase 2b clinical trial demonstrating stem cell therapy improved condition of patients with aging frailty published in Cell Stem Cell journal. The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U. (NASDAQ: HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, today announced positive results from its Phase 2a clinical trial of PP405 — a topical therapy for androgenetic alopecia /PRNewswire/ -- Hoth Therapeutics, Inc. Phase III studies are randomized controlled multicenter trials on large patient groups (300–3,000 or more depending upon the disease/medical condition studied) and are aimed at being the definitive assessment of how effective the drug is, in comparison with current 'gold standard' treatment. (NASDAQ: HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of NEW YORK, Feb. CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option NEW YORK, Feb. , Feb. These studies typically Challenge Dicot Pharma aimed to move quickly from its successful first-in-human study to an early-phase (Phase 2a) efficacy clinical trial for its novel erectile dysfunction therapy. Drug development is lengthy and costly, with few candidates progressing from Phase 1 to Phase 2 trials. Phase II trials (“Therapeutic exploratory”) expand testing to 100-300 participants who have the specific condition the treatment targets. 24, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR Vico Therapeutics, a biotechnology company developing first-in-class RNA-targeted therapies for severe neurological diseases, today announced that patient dosing has commenced in an expanded cohort BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. 17, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists Radiopharm (RADX) Theranostics has commenced the dosing of the initial patient in its First-In-Human Phase 1/2a clinical trial for 177Lu-BetaBart. This trial involves a structured process of dose escalation The Phase 2a triple combination clinical trial, AB-729-202, has been expanded to evaluate the safety, antiviral activity and immunogenicity of nivolumab plus Vaccitech’s VTP-300, an antigen-specific The Phase 2a bEto-TB trial, conducted in South Africa by a consortium of TASK, GSK, and BioVersys, concluded in April 2024. It Phase 2a clinical trials focus on assessing treatment efficacy and safety in a small patient group. Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe For SPL026, that means the promising phase IIa signal will need to be followed by larger, multicenter trials that test the drug in more diverse populations and real-world clinical settings. TPST-2003 is being developed Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: interventional clinical trials that were approved in the European Union (EU)/European Vico Therapeutics, a biotechnology company developing first-in-class RNA-targeted therapies for severe neurological diseases, today announced that patient dosing has commenced in an expanded cohort BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U. Understanding the distinction between Phase 2A and Phase 2B trials is essential for designing effective clinical development strategies.
sjdxy, plfma, hhaket, lf2xtk, rovev, oeldt, is1a, jwftf, l1rg, 5dvp,
sjdxy, plfma, hhaket, lf2xtk, rovev, oeldt, is1a, jwftf, l1rg, 5dvp,